How cannabinoids may slow brain aging. Szalavitz, Maia Time, 2012 Oct 29.
Cannabinoid modulation of neuroinflammatory disorders. Saito, Viviane M., et al. Current Neuropharmacology, 2012 Jun, 10(2): 159-166.
Terpenoids as potential anti-alzheimer’s disease therapeutics. Yoo, Ki-Yeol, et al. Molecules, 2012 Mar 12, 17(3): 3524-3528.
The therapeutic potential of the endocannabinoid system for alzheimer’s disease. Karl, Tim, et al. Expert Opinion on Therapeutic Targets, 2012 Apr, 16(4): 407-420.
An introduction to the medical benefits of cannabis. Acton, Jeremy, et al. NORML, 2011 Apr 4.
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to alzheimer’s disease. Martin-Moreno, Ana Maria, et al. Molecular Pharmacology, 2011 Feb 24, 79(6): 964-973.
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. Bisogno, Tiziana, et al. CNS and Neurological Disorders: Drug Targets, 2010 Nov, 9(5): 564-573.
Cannabinoid system in neurodegeneration: new perspectives in alzheimer’s disease. Campillo, N.E., et al. Mini Reviews in Medicinal Chemistry, 2009 May, 9(5): 539-559.
Alzheimer’s disease; taking the edge off with cannabinoids? Campbell, VA, et al. British Journal of Pharmacology, 2009 Jan 29, 152(5): 655-662.
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Zuardi, Antonio Waldo Revista Brasileira de Psiquiatria, 2008 Sep, 30(3).
The role of the endocannabinoid system in alzheimer’s disease: facts and hypothesis. Bosogno, Tiziana, et al. Current Pharmaceutical Design, 2008 Aug, 23(14): 2299-2305.
Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Fernandez-Ruiz, Javier, et al. Trends in Pharmacological Sciences, 2007 Jan, 28(1): 39-45.
A molecular link between the active component of marijuana and alzheimer’s disease pathology. Eubanks, Lisa M, et al. Molecular Pharmaceutics, 2006 Aug 9, 3(6): 773-777.
Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kB involvement. Esposito, Giuseppe, et al. Neuroscience Letters, 2006 May 15, 399(1-2): 91-95.
The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. Esposito, Giuseppe, et al. Journal of Molecular Medicine, 2006, 84(3): 253-258.
A molecular link between the active component of marijuana and alzheimer’s disease pathology. Eubanks, Lisa M., et al. Molecular pharmaceutics, 2006, 3(6): 773-777.
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Ehrhart, Jared, et al. Journal of Neuroinflammation, 2005 Dec 12, 2(29).
Prevention of alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Ramirez, Belen G, et al. The Journal of Neuroscience, 2005 Feb 23, 25(8): 1904-1913.
Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. Iuvone, Teresa, et al. Journal of Neurochemistry, 2004 Apr, 89(1): 134-141.
The therapeutic potential of cannabis. Baker, David, et al. The Lancet Neurology, 2003 May, 2(5): 291-298.
Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Mazzola, Carmen, et al. European Journal of Pharmacology, 2003 Sep 23, 477(3): 219-225.
Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Facchinetti, Fabrizio, et al. GLIA, 2003 Jan 15, 41(2): 161-168 (Full).